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Abstract 
 
INTRODUCTION: The gabapentinoids pregabalin and gabapentin are being increasingly 
prescribed for a range of clinical conditions. Recently, although gabapentinoids at therapeutic 
dosages may present with low addictive liability levels, cases of misuse and rising numbers of 
related fatalities have been reported.  
OBJECTIVES: The aim of the study was to identify and assess cases of gabapentinoid misuse or 
dependence as reported to the European Medicines Agency’s EudraVigilance (EV) database, in 
order to identify the magnitude of this problem and the characteristics of these reactions. 
METHODS: All spontaneous reports of both gabapentin- (2004-2015) and pregabalin- (2006-
2015) related misuse/abuse/dependence were retrieved. A descriptive analysis by source, sex, age, 
and type of report was performed. 
RESULTS: From the EV database 7,639 (6.6% of a total of 115,616), and 4,301 (4.8% of 90,166) 
ADR reports of misuse/abuse/dependence were, respectively, associated with pregabalin and 
gabapentin, with an overall reporting frequency increasing over time. For both molecules, subjects 
typically involved were adult females.  A total of 27 and 86 fatalities, respectively, associated with 
pregabalin and gabapentin, and mostly in combination with opioids, were identified. Analysis of 
proportional reporting ratios (PRR) for drug abuse/dependence/ intentional product misuse values 
seem to indicate that these ADRs were more frequently reported for pregabalin (1.25; 1.39; 1.58, 
respectively) compared to gabapentin. 
CONCLUSIONS: Despite data collection/methodological approach limitations, the present data 
seem to suggest that gabapentinoid misuse may be a cause for concern, especially in patients with a 
history of substance misuse. Hence, healthcare professionals should be vigilant when prescribing 
these molecules. 
 
  
 
Key points:  
- Consistent with increasing levels of prescriptions and rising numbers of related fatalities, 
pregabalin and gabapentin have recently been reported as possessing addictive liability. Misusers 
may ingest these molecules in order to achieve euphoric/dissociative effects. 
- The present study aimed to identify and assess cases of gabapentinoid misuse/dependence as 
reported to the EMA’s EudraVigilance (EV) database. 
-Despite data collection/methodological approach limitations, the present data suggest that 
gabapentinoid misuse may be a cause for concern, especially in patients with a history of substance 
misuse. 
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1. INTRODUCTION 
The gabapentinoids pregabalin and gabapentin were originally developed as anticonvulsants and are 
now increasingly [1] and widely prescribed for a range of clinical conditions [2]. Recently, 
however, both drugs have been reported as possessing a distinct potential for misuse [3-8]. 
Although gabapentinoids at therapeutic dosages may present with a low addictive liability potential, 
misusers may ingest these molecules in order to achieve euphoric and dissociative effects similar to 
those of traditional recreational drugs [9-15]. 
Pregabalin is authorized in the European Union for epilepsy, neuropathic pain, and generalized 
anxiety disorder [16], with fibromyalgia being considered an additional indication in the US [17]. 
Pregabalin can also be effective in the treatment of benzodiazepine dependence, post-traumatic 
stress disorder, and alcohol dependence, even though it is not currently approved for the treatment 
of these conditions [2; 18]. In the US, pregabalin is a Schedule V drug (e.g. drugs with limited 
potential for abuse) [19]. However, signals for the dependence potential of pregabalin were 
identified as early as 2004 in the UK [20] and in 2005 worldwide [21], with overall cases 
progressively increasing since 2008 [22]. History of substance misuse is typically associated with 
overuse of pregabalin [23-26]. Although tolerance to pregabalin has not been proven [27-28], its 
withdrawal syndrome may include agitation/anxiety, craving, sweating, insomnia, fatigue, 
palpitations, tremors, and diarrhoea [29-33]. 
Gabapentin is approved to treat epilepsy and neuropathic pain disorders [4; 34], with off-label use 
of the molecule including restless legs syndrome, migraine, vasomotor symptoms of menopause, 
and alcohol and substance dependence [2; 35-38]. There are anecdotal reports of its misuse [39], 
particularly in cocaine users and prison settings [40-41]. A gabapentin withdrawal syndrome, with 
features similar to those reported with pregabalin, has been described [42-43].  
Gabapentinoids selectively bind to the α2-δ subunit of voltage-gated calcium channels in central 
nervous system neuronal tissues. As a result, GABA levels increase in parallel with the inhibition of 
the release of excitatory neurotransmitters, possibly accounting for the antinociceptive, 
anticonvulsant, anxiolytic, and sleep-modulating activities of gabapentinoids [44]. It remains to be 
confirmed if gabapentinoid ingestion is associated with meaningful levels of dopamine reward 
pathway activation [45-46]. Even though pregabalin and gabapentin share similar mechanisms of 
action, they differ in their pharmacokinetic and pharmacodynamic characteristics. Indeed, 
pregabalin binding affinity for the α2-δ subunit, and potency, is six times higher than that of 
gabapentin. The putative higher addiction potential of pregabalin in comparison with gabapentin 
may be due, as well, to a range of factors, including more rapid absorption, faster onset of 
action/attainment of maximum plasma concentration [47], and higher bioavailability, which remains 
at >90% irrespective of the dosage (for a review, see [48]).  
The European Medicines Agency (EMA) is responsible for the scientific evaluation, supervision 
and safety monitoring of medicines developed for use in the European Union (EU). The EMA 
coordinates the EU pharmacovigilance system, including managing the EudraVigilance (EV) [49] 
database since 2001. The EV database is the central database of electronic reports of suspected 
adverse drug reactions (ADRs) for all medicinal products authorised in the European Economic 
Area (EEA; including 28 European countries together with Iceland, Liechtenstein and Norway 
[50]). ADRs are reported to the EV database by Regulatory Authorities of the Member States where 
the reaction occurred, as well as by the Marketing Authorisation Holders for ADRs occurring 
outside the EEA. The suspected ADRs originate from ‘spontaneous case reports’, defined as 
follows: ‘an unsolicited communication by a healthcare professional, or consumer, to a competent 
authority …. that describes one or more suspected adverse reactions in a patient who was given one 
or more medical products ….’ [51].  
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The aim of this study was to identify and assess cases of gabapentinoid misuse, abuse or 
dependence reported to the EMA’s EV database, in order to identify the magnitude of this problem 
and the characteristics of these reactions.  
 
2. METHODS 
Following a formal request, the EMA allowed us to access the tabulated information available from 
the EV database on case reports of pregabalin- and gabapentin- related ADRs. Search periods for 
pregabalin and gabapentin differed because they presented with different approval/commercial 
availability times. 
The EV database defines an ADR as ‘an undesirable effect, a response to a medicinal product which 
is noxious and unintended’. The EV database also considers ‘reporting’ as a causal relationship 
between a medicinal product and an adverse event which is at least a reasonable possibility. 
Adverse reactions may arise from use of the product within or outside the terms of the marketing 
authorisation. Conditions of use outside the marketing authorisation include off-label use, overdose, 
misuse, abuse and medication errors. Data in the EV system are coded against the extended 
EudraVigilance Medicinal Product Dictionary (XEVMPD) [51]. ADRs are listed by ‘Preferred 
Terms’ (PTs) and grouped by ‘System Organ Class’ (SOC) of the Medical Dictionary for regulatory 
Activities (MedDRA), supporting the coding of adverse reactions [52]. Within the standardised 
MedDRA Query (SMQ) ‘drug abuse, dependence and withdrawal’ section, we identified the 
following adverse reactions associated with gabapentin and pregabalin: ‘drug abuse’, ‘drug abuser’, 
‘drug dependence’, ‘intentional product misuse’, ‘intentional product use issue’, ‘polysubstance 
dependence’, ‘substance abuse’, ‘substance abuser’, and ‘drug withdrawal syndrome’. In 
accordance with MedDRA definitions [53], we referred here to ‘misuse’ as the intentional and 
inappropriate use of a product other than as prescribed or not in accordance with the authorized 
product information. Conversely, ‘abuse’ is the intentional, non-therapeutic, use of a product for a 
perceived reward or desired non-therapeutic effect including, but not limited to, ‘getting 
high’/euphoria. Finally, ‘addiction’ (typically replaced by ‘dependence’ [54]), is here the 
overwhelming desire to take a drug for non-therapeutic purposes together with inability to control 
or stop its use despite harmful consequences. 
In the analysis here performed, the number of ADRs could be different from the number of case 
reports as one case report may refer to several ADRs. Furthermore, different reporters/senders could 
have independently signaled the ADR to the EMA. Within the EV database, the reporter is the 
primary source of the information, i.e. the person who actually reports the facts. The reporter is 
identifiable by name, initials, address, and qualifications (e.g. physician, pharmacist, other 
healthcare professional, lawyer, consumer or other non-health professional), although local data 
privacy laws regarding both patient and reporter identity might typically apply. Conversely, the 
sender is the person or entity creating the message for transmission, with the reporter and the sender 
being at times the same person. Each case/individual patient in the database has a code (EV local 
number) for identification. Hence, the number of cases or individual patients was unequivocally 
identified counting the number of values in the EV local number column of the ADRs’ database 
using a worksheet function. The EV database considers the ‘drug role’ as the assessment of the 
relationship between respectively pregabalin or gabapentin prescription and the reported 
observation of abuse/dependence. 
Cases were analysed considering a range of parameters, including: age and gender of the patient; 
source/reporter country; sender type; reporter qualification; outcome(s); concomitant drug(s); and 
drug’s role. Two different ‘line listings’, one for each drug, were received via EudraLink, e.g. a 
secure electronic system. The databases discussed include all case reports submitted as 
‘spontaneous’ to the EV database up to mid-July 2015.  
To more properly compare pregabalin vs gabapentin, the proportional reporting ratios (PRR) 
approach was here considered as well. This is a measure of disproportionality of reporting used to 
detect ADRs in pharmacovigilance databases such as the EV. A PRR greater than 1 suggests that 
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the adverse event is more commonly reported for individuals taking the drug of interest, relative to 
the comparison drug(s). The PRR is defined as the ratio between the frequency with which a 
specific adverse event is reported for the drug of interest (relative to all adverse events reported for 
the drug) and the frequency with which the same adverse event is reported for the drug(s) in the 
comparison group (relative to all adverse events for drugs in the comparison group).  
The PRR is computed as follows:                  A/A+B 
                                                                       C/C+D 
(where: A is the number of individual cases with pregabalin involving the adverse events drug 
abuse/drug dependence/intentional product misuse; B is the number of individual cases related to 
pregabalin involving any other adverse events; C is the number of individual cases involving the 
events drug abuse/drug dependence/intentional product misuse in relation to gabapentin; and D 
indicates the number of individual cases involving any other adverse events associated with 
gabapentin) [55]. 
All EV database suspected ADR case reports here discussed have been partially redacted in 
accordance with Regulation (EC) No 45/2001 of the European Parliament and of the Council of 18 
December 2000 on the protection of individuals with regard to the processing of personal data by 
the Community institutions and bodies and on the free movement of such data.  
 
3. RESULTS 
For both pregabalin and gabapentin, most reports originated from north America, followed by east 
Asia and south America, whilst EEA pharmaceutical companies represented the most typical 
senders. The drug role was typically considered to be ‘suspect’.  
 
3.1 PREGABALIN ADRs 
Over the period 03/2006-15/07/2015, the EMA received 115,616 ADRs reports relating to 
pregabalin; this molecule had been approved by the EMA in 2006, when gabapentin was already 
available. Out of these, 7,639 reports were relating to abuse/dependence/product misuse issues, 
corresponding to 1,315 patients and 6.61% of all ADRs recorded. The number of reports increased 
consistently year-per-year (Figure 1), with a peak in 2013 (2,154 reports) and a decrease in 2014 
(1,593 reports), reaching 1,387 by July 15th, 2015. Using the SMQ terms, 32.2% were classified as 
‘intentional product misuse’, 31.9% as ‘drug dependence’, and 22.3% as ’drug abuse’. Overall, 
typical subjects here involved were adult females (F/M ratio: 1.13/1), although a gender uneven 
distribution was seen as well in all ADRs reports (F/M ratio: 3.08/1). Index drugs reported to be 
most concurrently misused in combination with pregabalin included opioids (identified in n=791; 
10.35% of ADRs), antidepressants and benzodiazepines.  
 
3.2 GABAPENTIN ADRs 
Over the period 03/2004-15/07/2015, the EMA received 90,166 ADRs reports relating to 
gabapentin. Out of these, 4,301 were relating to abuse/dependence issues, corresponding to 410 
patients and 4.77% of all ADRs recorded.  The number of reports increased consistently year-per-
year (Figure 1). Using the SMQ terms, 28.3% were classified as ‘intentional product misuse’; 
31.8% as ‘drug dependence’; and 24.8% as ’drug abuse’. Overall, typical subjects involved here 
were adult females (F/M ratio: 1.27/1), although a gender uneven distribution was seen as well in all 
ADRs reports (F/M ratio: 2.1/1). Index drugs reported to be most concurrently misused with 
gabapentin were opioids (identified in n=555; 12.9% of ADRs), antidepressants and 
benzodiazepines. 
 
3.3 PREGABALIN VS GABAPENTIN; PRR COMPUTATION  
Table 1 presents the data relating to ‘pregabalin vs gabapentin’ PRR calculations whilst considering 
the three most represented ADRs, e.g. drug abuse; drug dependence; and intentional product 
misuse.  
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The resulting PRR values suggest that these ADRs were more frequently reported for pregabalin 
(respectively: 1.25; 1.39; 1.58) compared to gabapentin. As an example, the PRR for A1/drug abuse 
has been computed as follows: 
 
A1/A1+B=   1706/(1706+109007)= 0.015 =1.25 
C1/C1+D     1066/(1066+86513)     0.012 
 
3.4 RELATED FATALITIES 
In the 1,315-patient pregabalin group, 27 (2.05%) fatality reports were identified, but only in 5 
cases the drug was reported on its own. Thirteen cases involved adult females, and 10 cases had 
occurred in 2014. Most reports were sent by a physician (10 cases) and originated from outside the 
EEA (11 cases).   
Conversely, in the 410-patient gabapentin group, 86 (21%) fatalities were identified and in 3 cases 
gabapentin was reported on its own. Fifty-one cases involved adult females, and 23 cases had 
occurred in 2014. Most (78 cases) reports originated from outside the European area.  
In association with pregabalin and gabapentin, opioids were the concomitant drugs most typically 
identified, followed by antidepressants and benzodiazepines. A range of recreational substances 
(e.g. alcohol, amphetamines, cannabis, and ketamine) was at times identified as well. 
 
4. DISCUSSION 
To the best of our knowledge, this is the first and largest scale study aimed at identifying and 
analysing gabapentinoid misuse/dependence issues as reported to a pharmacovigilance database 
such as the EMA’s EVdatabase. This database, together with the WHO's Drug Monitoring 
Programme [56], is considered a world-wide reference standard [57]. As expected, EEA 
pharmaceutical companies were identified as the most typical spontaneous reporters. 
Overall, 7,639 (6.6% out of a total of 115,616), and 4,301 (4.8% of 90,166) ADR reports were, 
respectively, relating to pregabalin and gabapentin abuse/dependence issues. These figures are 
somewhat higher than those extracted from a German database query, which reviewed any 
pregabalin-related ADRs and found that 55 of 1,552 reports (3.5%) related to pregabalin 
abuse/dependence issues [58]. Regarding gabapentin, very recent reports have highlighted that 20% 
of patients in treatment may misuse/abuse with this molecule and that accident and emergency visits 
involving the nonmedical use of gabapentin have increased by 90% in the United States since 2008 
[59].  
The PRR values that we calculated suggested that abuse/dependence issues were more frequently 
reported for pregabalin compared to gabapentin. This may be explained by a range of contributory 
factors, including higher addictive liability of pregabalin in comparison to gabapentin [4], and a 
larger range of clinical conditions being considered by clinicians in choosing between pregabalin 
and gabapentin. Indeed, apart from neuropathic pain, pregabalin can be prescribed for anxiety as 
well, a condition which has in turn been associated with a vulnerability to addiction [60-61]. Hence, 
different from gabapentin, with pregabalin there are more chances of prescribing to subjects who 
are psychologically vulnerable/arguably more prone to substance misuse.  
The present data may support the idea of overall increasing levels of gabapentinoid misuse reports 
over time, a narrative consistent with previous observations made with traditional psychoactives, 
e.g. benzodiazepines. These molecules were considered safe for many years before their addictive 
liability levels were identified [62].  
Overall, the female gender was more represented in all ADRs received by the EMA, including the 
abuse/dependence cases. Indeed, excluding epilepsy [63], gabapentinoids are prescribed to treat 
disorders which are more typically identified in females, including chronic/neuropathic pain [64], 
generalized anxiety disorder [65], fibromyalgia [66], restless legs syndrome [67], migraine [68] and, 
of course, vasomotor symptoms of menopause.  
7 
In the EV database, 27 pregabalin- and 86 gabapentin-related fatality reports were  identified. 
Although this finding is in itself interesting, to be able to calculate properly the gabapentinoid ‘fatal 
toxicity index’ [69] one would need to have the total number of patients exposed to either 
pregabalin or gabapentin. In contrast to pregabalin, which has already been extensively identified in 
forensic toxicological analysis [6], gabapentin acute toxicity/morbidity incidents have previously 
been identified only in patients with a compromised renal function [70-71]. In the UK, overall, the 
number of post-mortem cases in which gabapentinoids were implicated has progressively increased 
since 2006 [5]. Consistent with the present data, opioids and alcohol were identified in 90% and 
15%, respectively, of gabapentinoid-related fatalities that occurred during 2010-2011 in Finland 
[72]. Similarly, opioids were implicated in most (66%) overdose-related deaths involving 
antiepileptics in the US [73]. Opioids may have been prescribed here to potentiate gabapentinoid 
analgesic effects for treating specific medical conditions/intractable pain. However, gabapentin 
bioavailability may increase by 50% when co-administered with morphine [48]. Furthermore, 
gabapentinoids contribute to the elderly sedative load and corresponding risk of falls [74]. Finally, 
gabapentinoids may be ingested by opioid addicts to potentiate the substitute opiates/opioids’ 
psychoactive effects [75-78].  
 
5. LIMITATIONS 
Case reports of suspected ADRs alone are rarely sufficient to confirm that a certain effect in a 
patient has been caused by a specific medicine. The fact that a suspected adverse reaction has been 
reported does not necessarily mean that the medicine has caused the observed effect, as this could 
have also been caused by the disease being treated, a new disease the patient developed, or by 
another medicine that the patient is taking. Furthermore, the number of case reports for a particular 
medicinal product depends as well on its availability in the market and its extent of use, the nature 
of the reaction and public awareness of a safety concern. Hence, comparing the number of case 
reports between medicines may give a misleading picture of their safety profiles. Furthermore, 
spontaneous reports were likely to reflect here issues relating to prescribed gabapentinoids only, 
whilst these molecules are widely available from rogue websites [14] and, in some countries, over-
the-counter as well. 
It appears from our data that there were a number of ADRs relating to the same patient. This may 
have happened because of a range of different sources reporting the same ADR but also because for 
the same patient a number of different ADRs may have been reported. Furthermore, full levels of 
information regarding the subjects’ possible psychiatric/drug misuse history were not available, and 
the gabapentinoid abuse/dependence diagnosis was not made in accordance with international 
classifications standards. Overall, both reporting and publication bias may have occurred. In fact, 
the recently increasing number of literature papers highlighting the addictive liability of 
gabapentinoids [4] may have facilitated the related spontaneous reporting levels. Finally, a PRR 
exceeding 1 could also reflect sampling variation in the data, reporting errors, biased reporting, 
multiple reports of the same case or the same patient, or a number of other causes. 
 
6. CONCLUSIONS 
Despite data collection limitations, the data presented in this paper seem to confirm the misuse 
potential of gabapentinoids. Whether or not this misuse is occurring on a large scale cannot be 
confirmed from our data. As the EV database reports were submitted spontaneously, present figures 
may however represent an underestimate of the problem. Further, prospective, studies should be 
encouraged to better assess the addictive liability of gabapentinoids, particularly because these 
drugs are under investigation for the treatment of substance related disorders, specifically 
benzodiazepine and alcohol withdrawal [2]. Healthcare professionals should be vigilant when 
prescribing these molecules, particularly in both patients with a substance misuse history [4; 17; 
79], and inmates [41; 80]. Due to the possibility of diversion, amount of drug prescribed per 
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individual prescription should be limited and, if any related misuse issues are identified, physicians 
should consider medication tapering.  
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